ADT PHARMACEUTICALS, LLC
DC070-547, a small-molecule inhibitor that selectively targets tumor cells with activated Ras mutations by disrupting Ras-Raf interactions
- Sector
- Biotech
- Total capital
- $1.1M
- Federal grants
- $827K
- 4 awards · 2015–2018
- Rank in peer group#52 of 502
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $300K
- 1 award · Health and Human S
- Rank in Biotech#268 of 4373
- Granted patents
- 10
- 2 pending · first 2020
- Rank in peer group#9 of 502
Capital timeline
Latest events
- Federal contractHealth and Human S · Topic 386: Novel Orally Bioavailable Pde -catenin Inhibitor Concentrates In Lung For Cancer Chemoprevention$300K
- Federal grantHealth and Human S · Phase I · Oral formulation for novel inhibitor of Ras driven cancers$2K
- Federal grantHealth and Human S · Phase I · Oral formulation for novel inhibitor of Ras driven cancers$300K
- Federal grantHealth and Human S · Phase I · Novel Ras inhibitor prodrug for colorectal cancer$300K
- Federal grantHealth and Human S · Phase I · A novel phosphodiesterase isozyme target and class of inhibitors for lung cancer$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#52 · top 10%
- Granted patents#9 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 10 granted of 12- GrantedMethod Of Therapeutically Treating CancerUSPTOUS 12,479,813
- GrantedAnticancer Indenes, Indanes, Azaindenes, Azaindanes, Pharmaceutical Compositions And UsesUSPTOUS 11,680,073
- GrantedIndenyl Compounds, Pharmaceutical Compositions, And Medical Uses ThereofUSPTOUS 11,407,727
Show all 12 patent records
- Method Of Therapeutically Treating CancerNov 25, 2025 · US 12,479,813Granted
- Anticancer Indenes, Indanes, Azaindenes, Azaindanes, Pharmaceutical Compositions And UsesJun 20, 2023 · US 11,680,073Granted
- Indenyl Compounds, Pharmaceutical Compositions, And Medical Uses ThereofAug 9, 2022 · US 11,407,727Granted
- Method Of Treating Or Preventing Ras-mediated DiseasesDec 14, 2021 · US 11,198,679Granted
- Anticancer Indenes, Indanes, Azaindenes, Azaindanes, Pharmaceutical Compositions And UsesNov 30, 2021 · US 11,186,596Granted
- Indenyl Compounds, Pharmaceutical Compositions, And Medical Uses ThereofSep 28, 2021 · US 11,130,744Granted
- Method Of Treating Or Preventing Ras-mediated DiseasesAug 31, 2021 · US 11,104,658Granted
- Indenyl Compounds, Pharmaceutical Compositions, And Medical Uses ThereofApr 20, 2021 · US 10,981,886Granted
- Indenyl Compounds, Pharmaceutical Compositions, And Medical Uses ThereofApr 13, 2021 · US 10,975,054Granted
- Indenyl Compounds, Pharmaceutical Compositions, And Medical Uses ThereofJan 7, 2020 · US 10,526,307Granted
- Anticancer Indenes, Indanes, Azaindenes, Azaindanes, Pharmaceutical Compositions And UsesApplication PCTUS2019029430Pending
- Anticancer Indenes, Indanes, Azaindenes, Azaindanes, Pharmaceutical Compositions And UsesApplication 62662999Pending
Related companies, and why
- GENECURE LLCSimilar federal contract value in Biotech · $300K in contracts
- Coordination Pharmaceuticals IncSimilar federal contract value in Biotech · $300K in contracts
- Regulus Therapeutics Inc.Similar federal contract value in Biotech · $300K in contracts
- NECTAGEN INCSimilar federal contract value in Biotech · $300K in contracts
- HYLAPHARM LLCSimilar federal contract value in Biotech · $300K in contracts
- Ribonova Inc.Similar federal contract value in Biotech · $299K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .